The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 03, 2017

Filed:

Jun. 06, 2012
Applicants:

Iqbal Grewal, Snohomish, WA (US);

Michael Gresser, Ojai, CA (US);

Sanjay Khare, Palo Alto, CA (US);

Rashid Syed, Thousand Oaks, CA (US);

Inventors:

Iqbal Grewal, Snohomish, WA (US);

Michael Gresser, Ojai, CA (US);

Sanjay Khare, Palo Alto, CA (US);

Rashid Syed, Thousand Oaks, CA (US);

Assignee:

IMMUNGENE INC, Camarillo, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 19/00 (2006.01); C07K 14/525 (2006.01); C07K 16/28 (2006.01); A61K 38/19 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 14/475 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2887 (2013.01); A61K 38/191 (2013.01); A61K 38/212 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); C07K 14/525 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01);
Abstract

The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN®), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-α, CD40L, CD95L (also 'FasL/Apo-1L') and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities.


Find Patent Forward Citations

Loading…